Therapeutical Class：Carbapenems, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): not for MRSA; G(-); anaerobes.

Administraton：IV.

Adults: 1.5-6 g/ day divided in 3 doses.

Pseudomonas, intra-abdominal infections, febrile neutropenia, otitis externa, pneumonia, skin and skin structure infections (complicated), UTI (complicated):

1 g q8h.

Meningitis: 2 g q8h.

Children: 30-120 mg/kg/day in divided 3 doses, max: 6 g/day.

Renal impairment: Ccr 26-50 ml/min, 0.5-2 g (full-dose) q12h;

Ccr 10-25 ml/min, half-dose q12h;

Ccr <10 ml/min, half-dose q24h.

Adverse Effect：Hypersensitivity, renal failure, nausea, diarrhea (1-10%), pseudomembranous colitis, seizure, rash (1-10%), pruritus, anemia, constipation (1-10%), thrombocytopenia, jaundice, hepatic failure, hypoprothrombinemia, bleeding, headache (1-10%).

Contraindication：Hypersensitivity to carbapenems.

Pregnancy Risk：B

Supply：Mepem XE “Mepem” IV Inj 0.25gm/vial（美平乾粉注射劑 Sumitomo）＜11391＞